M. Versola

538 total citations
22 papers, 456 citations indexed

About

M. Versola is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, M. Versola has authored 22 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Genetics. Recurrent topics in M. Versola's work include Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (11 papers) and HER2/EGFR in Cancer Research (10 papers). M. Versola is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (11 papers) and HER2/EGFR in Cancer Research (10 papers). M. Versola collaborates with scholars based in United States, Netherlands and United Kingdom. M. Versola's co-authors include Kevin M. Koch, Deborah A. Smith, Lini Pandite, Ronald A. Fleming, Suzanne F. Jones, Neil L. Spector, Andrew G. Stead, Howard A. Burris, H. A. Burris and Charles W. Taylor and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

M. Versola

22 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Versola United States	13	368	173	97	88	65	22	456
Mahmoud Ould-Kaci France	10	429 1.2×	245 1.4×	125 1.3×	52 0.6×	42 0.6×	17	540
Karen Giselle Chee United States	7	182 0.5×	163 0.9×	102 1.1×	40 0.5×	65 1.0×	9	380
Sang Hyung Lee South Korea	6	293 0.8×	78 0.5×	96 1.0×	29 0.3×	94 1.4×	7	441
Christa G.M. Gadellaa-van Hooijdonk Netherlands	6	349 0.9×	121 0.7×	106 1.1×	35 0.4×	44 0.7×	7	506
Rodrigo Ruiz-Soto United States	9	186 0.5×	90 0.5×	174 1.8×	44 0.5×	66 1.0×	19	408
Tuan S. Nguyen United States	10	150 0.4×	80 0.5×	133 1.4×	41 0.5×	26 0.4×	19	338
Herb Kotz United States	11	325 0.9×	130 0.8×	148 1.5×	20 0.2×	20 0.3×	23	494
Yoojoo Lim South Korea	14	201 0.5×	117 0.7×	162 1.7×	56 0.6×	58 0.9×	56	485
Corrado Gallo Stampino Italy	12	238 0.6×	103 0.6×	183 1.9×	27 0.3×	20 0.3×	31	419
Laurence Hatteville France	8	295 0.8×	67 0.4×	70 0.7×	46 0.5×	92 1.4×	10	384

Countries citing papers authored by M. Versola

Since Specialization

Citations

This map shows the geographic impact of M. Versola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Versola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Versola more than expected).

Fields of papers citing papers by M. Versola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Versola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Versola. The network helps show where M. Versola may publish in the future.

Co-authorship network of co-authors of M. Versola

This figure shows the co-authorship network connecting the top 25 collaborators of M. Versola. A scholar is included among the top collaborators of M. Versola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Versola. M. Versola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

O’Neil, Bert H., Johanna C. Bendell, Manuel Modiano, et al.. (2013). Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.. Journal of Clinical Oncology. 31(4_suppl). 294–294. 20 indexed citations

2.

Burris, Howard A., Charles W. Taylor, Suzanne F. Jones, et al.. (2009). A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies. Clinical Cancer Research. 15(21). 6702–6708. 83 indexed citations

3.

Blagden, Sarah P., David Olmos, Rakesh Kumar Sharma, et al.. (2008). Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer. European Journal of Cancer Supplements. 6. 135–135. 2 indexed citations

4.

Blagden, Sarah P., David Olmos, Rohini Sharma, et al.. (2008). 431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors. European Journal of Cancer Supplements. 6(12). 135–136. 2 indexed citations

5.

Midgley, Rachel, Rachel Kerr, Keith T. Flaherty, et al.. (2007). A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Annals of Oncology. 18(12). 2025–2029. 43 indexed citations

6.

Chu, Quincy S., Garry Schwartz, Johann S. de Bono, et al.. (2007). Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology. 25(24). 3753–3758. 48 indexed citations

7.

Beijnen, Jos H., Walter L. Vervenne, Henk Boot, et al.. (2007). Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors. Clinical Cancer Research. 13(15). 4495–4502. 41 indexed citations

8.

Midgley, Rachel, Keith T. Flaherty, D.G. Haller, et al.. (2005). Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV). Journal of Clinical Oncology. 23(16_suppl). 3086–3086. 12 indexed citations

9.

Schwartz, Garry, Quincy Chu, L. A. Hammond, et al.. (2004). Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3070–3070. 20 indexed citations

10.

Lilenbaum, Rogério, et al.. (2004). Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Annals of Oncology. 16(1). 97–101. 30 indexed citations

11.

Jones, Suzanne F., John D. Hainsworth, David R. Spigel, et al.. (2004). A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009). Journal of Clinical Oncology. 22(14_suppl). 2083–2083. 14 indexed citations

12.

Burris, H. A., Stacey A. Jones, Cindy C. Taylor, et al.. (2004). A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3179–3179. 11 indexed citations

13.

Versola, M., H. A. Burris, Suzanne F. Jones, et al.. (2004). Clinical activity of GW572016 in EGF10003 in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3047–3047. 22 indexed citations

14.

Westermann, Anneke M., M. Versola, Kevin M. Koch, et al.. (2004). Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2044–2044. 7 indexed citations

15.

Schwartz, Garry, Quincy Chu, L. A. Hammond, et al.. (2004). Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3070–3070. 13 indexed citations

16.

Jones, Suzanne F., John D. Hainsworth, David R. Spigel, et al.. (2004). A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009). Journal of Clinical Oncology. 22(14_suppl). 2083–2083. 9 indexed citations

17.

Versola, M., H. A. Burris, Sharon Jones, et al.. (2004). Clinical activity of GW572016 in EGF10003 in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3047–3047. 38 indexed citations

18.

Makower, Della, Joseph A. Sparano, Scott Wadler, et al.. (2003). A Pilot Study of Edrecolomab (Panorex, 17-1A Antibody) and Capecitabine in Patients with Advanced or Metastatic Adenocarcinoma. Cancer Investigation. 21(2). 177–184. 5 indexed citations

19.

Koch, Kevin M., Andrew G. Stead, M. Versola, et al.. (2003). 559 Pharmacokinetics of GW572016 in an ascending dose tolerability study of phase I cancer patients. European Journal of Cancer Supplements. 1(5). S169–S169. 11 indexed citations

20.

Koch, Kevin M., et al.. (2003). 558 The effect of food on the pharmacokinetics of GW572016. European Journal of Cancer Supplements. 1(5). S169–S169. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact